Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...
Benzinga.com3d
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
Get a high-probability setup with clear entry and exit points right here. Vertex Pharmaceuticals Inc VRTX announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said ...
Hosted on MSN1mon
Vertex Pharmaceuticals EVP sells shares worth $1.58 million
Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently executed a significant stock sale. According to a recent SEC filing ...
Yahoo Finance6d
Vertex Pharmaceuticals (VRTX) Stock Moves -1.96%: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...
Reuters1mon
Vertex Pharmaceuticals Inc
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of ...
Nasdaq2d
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...